TrialPharmacogenetics and genomics2014

CYP3A4*22 and CYP3A5*3 are associated with increased levels of plasma simvastatin concentrations in the cholesterol and pharmacogenetics study cohort.

Joseph P Kitzmiller et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.